Microbial Biotechnology最新文献

{"title":"Sterol-Targeted Laboratory Evolution Allows the Isolation of Thermotolerant and Respiratory-Competent Clones of the Industrial Yeast Saccharomyces cerevisiae","authors":"Isabel-Elena Sánchez-Adriá,&nbsp;Jose A. Prieto,&nbsp;Gemma Sanmartín,&nbsp;Miguel Morard,&nbsp;Estéfani García-Ríos,&nbsp;Francisco Estruch,&nbsp;Francisca Randez-Gil","doi":"10.1111/1751-7915.70092","DOIUrl":"10.1111/1751-7915.70092","url":null,"abstract":"<p>Sterol composition plays a crucial role in determining the ability of yeast cells to withstand high temperatures, an essential trait in biotechnology. Using a targeted evolution strategy involving fluconazole (FCNZ), an inhibitor of the sterol biosynthesis pathway, and the immunosuppressant FK506, we aimed to enhance thermotolerance in an industrial baker's yeast population by modifying their sterol composition. This approach yielded six isolates capable of proliferating in liquid YPD with μ_max values ranging from 0.072 to 0.236 h⁻¹ at 41.5°C, a temperature that completely inhibits the growth of the parental strain. The clones were categorised into two groups based on their respiratory competence or deficiency, the latter associated with mtDNA loss, an event seemingly linked to FCNZ and heat tolerance. Genome sequencing and ploidy-level analysis of all strains revealed aneuploidies, copy number variations (CNVs), and single nucleotide polymorphisms (SNPs). Notably, all evolved clones exhibited specific point mutations in <i>MPM1</i> (P50S) and <i>PDR1</i> (F749S). CRISPR-Cas9 experiments confirmed the role of the <i>pdr1</i>^F749S mutation in the FCNZ-tolerance phenotype and demonstrated that Mpm1 is required for growth at high temperatures. However, no apparent heat tolerance benefit was observed from single or combined mutations in these genes, supporting the hypothesis that thermotolerance is mediated by multiple interacting mechanisms. In this context, all evolved clones exhibited altered sterol profiles, with differences observed between respiratory-competent and -deficient strains. In conclusion, our experimental evolution generated thermotolerant and fully competent strains and identified factors that could influence fluconazole and heat growth.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbes Saving Lives and Reducing Suffering","authors":"Kenneth Timmis,&nbsp;Zeynep Ceren Karahan,&nbsp;Juan Luis Ramos,&nbsp;Omry Koren,&nbsp;Ana Elena Pérez-Cobas,&nbsp;Karen Steward,&nbsp;Victor de Lorenzo,&nbsp;Elisabetta Caselli,&nbsp;Margaret Douglas,&nbsp;Clarissa Schwab,&nbsp;Virginia Rivero,&nbsp;Rafael Giraldo,&nbsp;Junkal Garmendia,&nbsp;Raymond J. Turner,&nbsp;Jessamyn Perlmutter,&nbsp;José M. Borrero de Acuña,&nbsp;Pablo Ivan Nikel,&nbsp;Jerome Bonnet,&nbsp;Angela Sessitsch,&nbsp;James K. Timmis,&nbsp;Carla Pruzzo,&nbsp;M. Auxiliadora Prieto,&nbsp;Siavash Isazadeh,&nbsp;Wei E. Huang,&nbsp;Gerard Clarke,&nbsp;Danilo Ercolini,&nbsp;Max Häggblom","doi":"10.1111/1751-7915.70068","DOIUrl":"10.1111/1751-7915.70068","url":null,"abstract":"&lt;p&gt;Given the overexploitation of the resources of planet Earth, due in large part to the ever-increasing human population (https://www.un.org/sustainabledevelopment/sustainable-consumption-production/), which has already compromised vital planetary processes (https://reports.weforum.org/docs/WEF_Business_on_the_Edge_2024.pdf), the limitations of which are encapsulated in planetary boundaries (Richardson et al. &lt;span&gt;2023&lt;/span&gt;; Gupta et al. &lt;span&gt;2024&lt;/span&gt;; https://www.pik-potsdam.de/en/news/latest-news/earth-exceed-safe-limits-first-planetary-health-check-issues-red-alert) and climate tipping points (Wunderling et al. &lt;span&gt;2023&lt;/span&gt;; Wunderling, von der Heydt, and Aksenov &lt;span&gt;2024&lt;/span&gt;), it would not be unexpected that a visitor from Mars might well be confused, or at least bemused, by our efforts to save lives and reduce morbidity. The Martian might be similarly bemused when it learned that although warfare is a constant feature of biosphere ecology, including human behaviour, with military personnel of opposing armies doing their best to kill one another, military physicians will try their best to save the lives of injured prisoners of the opposing side. But warfare and other activities of individuals and groups aimed at harming others notwithstanding, saving lives and preventing/reducing human suffering is an ingrained moral-ethical-humanitarian imperative (https://www.ohchr.org/sites/default/files/Documents/Publications/Factsheet31.pdf). While we cannot prevent death, we try hard to prevent avoidable, premature death and disease. But trying hard is not the same as succeeding (Kruk et al. &lt;span&gt;2018&lt;/span&gt;). This is reflected in the United Nations Sustainable Development Goal (SDG) 3 &lt;i&gt;Ensure healthy lives and promote well-being for all at all ages&lt;/i&gt; which identifies major deficits in global healthcare and provides a roadmap to correct these deficits (https://sdgs.un.org/2030agenda).&lt;/p&gt;&lt;p&gt;The pursuit of saving lives and ameliorating human suffering is arguably the highest calling of humankind. Though generally considered to be the domain of clinicians—the healers—it clearly includes the endeavours of other health professionals, emergency responders, carers, parents–family–friends, the pharmaceutical industry, international organisations and a variety of non-governmental organisations. More indirectly it includes &lt;i&gt;inter alia&lt;/i&gt; those of engineers, educators, the body politic and financial services. Microbial technologies, exemplified by vaccines and microbially inspired and produced pharmaceuticals and diagnostics, play a central role in the prevention, amelioration and curing of disease, saving millions of lives and reducing billions of cases of suffering every year (https://immunizationdata.who.int). Moreover, life-saving microbial technologies play out not only in the healthcare sector but also in wastewater and drinking water monitoring and treatment (Fowler and Smets &lt;span&gt;2017&lt;/span&gt;), food provision, bioremediation, etc","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteria as Precision Tools for Cancer Therapy","authors":"Carmen Michán,&nbsp;José Prados,&nbsp;Juan-Luis Ramos","doi":"10.1111/1751-7915.70090","DOIUrl":"10.1111/1751-7915.70090","url":null,"abstract":"<p>The discovery at the end of the 20th century of genes that induce cell death revolutionised the biocontaintment of genetically manipulated bacteria for environmental or agricultural applications. These bacterial ‘killer’ genes were then assayed for their potential to target and control malignant cells in human cancers. The identification of the bacteriomes in different human organs and tissues, coupled with the observation that bacteria tend to accumulate near tumours, has opened new avenues for anti-cancer strategies. This progress, along with recent insights into how cancer cells evade immune response, has prompted innovative therapeutic approaches. Tumour microenvironments are typically nutrient-rich, characterised by low oxygen tensions and very resistant to immune responses. Two recent studies in MBT highlight the promise of using <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> as vectors in novel cancer treatments. Engineered <i>S. typhimurium</i> strains can generate adjuvant flagellin-antigen complexes that function as in situ vaccines, hence increasing the immunogenic responses within tumour environment. Similarly, gut <i>E. coli</i> can be used as vectors to targert tumour cells in colon cancer, enabling both diagnostic applications and localised treatments. Both approaches hold significant potential to improve patient survival outcomes.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prof. Manuel Espinosa Padrón (1942–2024): A Superb Plasmid Biologist and a Gentle Colossus","authors":"Tatiana Venkova,&nbsp;Dhruba Chattoraj","doi":"10.1111/1751-7915.70086","DOIUrl":"10.1111/1751-7915.70086","url":null,"abstract":"<p>Prof. Manuel Espinosa Padrón (1942–2024): A superb plasmid biologist and a gentle colossus.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Akkermansia muciniphila Mediated the Preventive Effect of Disulfiram on Acute Liver Injury via PI3K/Akt Pathway","authors":"Ruonan Zhang,&nbsp;Xuewei Sun,&nbsp;Han Lu,&nbsp;Xinrui Zhang,&nbsp;Mingyan Zhang,&nbsp;Xuewen Ji,&nbsp;Xinyi Yu,&nbsp;Chengliang Tang,&nbsp;Zihan Wu,&nbsp;Yinghua Mao,&nbsp;Jin Zhu,&nbsp;Minjun Ji,&nbsp;Zhan Yang","doi":"10.1111/1751-7915.70083","DOIUrl":"10.1111/1751-7915.70083","url":null,"abstract":"<p>Acetaminophen induced acute liver injury (ALI) has a high incidence and is a serious medical problem, but there is a lack of effective treatment. The enterohepatic axis is one of the targets of recent attention due to its important role in liver diseases. Disulfiram (DSF) is a multitarget drug that has been proven to play a role in a variety of liver diseases and can affect intestinal flora, but whether it can alleviate ALI is not clear. We utilised bacterial 16S rRNA gene profiling, antimicrobial treatments, and faecal microbiota transplantation tests to explore whether DSF therapy for ALI is dependent on gut microbiota. Our findings indicate that DSF primarily restores intestinal microbiome balance by modulating the abundance of <i>Akkermansia muciniphila</i> (<i>A. muciniphila</i>), leading to significant alleviation of ALI symptoms in a gut microbiota dependent manner. We also found that <i>A. muciniphila</i> can promote the activation of PI3K/Akt pathway, correct the Bcl-2/Bax ratio, and further inhibit hepatocyte apoptosis. In conclusion, DSF ameliorates ALI by modulating the intestinal microbiome and activating the PI3K/AKT pathway through <i>A. muciniphila</i>.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phage-Based Approach to Identify Antivirulence Inhibitors of Bacterial Type IV Pili","authors":"Tori M. Shimozono,&nbsp;Nancy J. Vogelaar,&nbsp;Megan T. O'Hara,&nbsp;Zhaomin Yang","doi":"10.1111/1751-7915.70081","DOIUrl":"10.1111/1751-7915.70081","url":null,"abstract":"<p>The increasing threat of antibiotic resistance underscores the urgent need for innovative strategies to combat infectious diseases, including the development of antivirulants. Microbial pathogens rely on their virulence factors to initiate and sustain infections. Antivirulants are small molecules designed to target virulence factors, thereby attenuating the virulence of infectious microbes. The bacterial type IV pilus (T4P), an extracellular protein filament that depends on the T4P machinery (T4PM) for its biogenesis, dynamics and function, is a key virulence factor in many significant bacterial pathogens. While the T4PM presents a promising antivirulence target, the systematic identification of inhibitors for its multiple protein constituents remains a considerable challenge. Here we report a novel high-throughput screening (HTS) approach for discovering T4P inhibitors. It uses <i>Pseudomonas aeruginosa,</i> a high-priority pathogen, in combination with its T4P-targeting phage, φKMV. Screening of a library of 2168 compounds using an optimised protocol led to the identification of tuspetinib, based on its deterrence of the lysis of <i>P. aeruginosa</i> by φKMV. Our findings show that tuspetinib also inhibits two additional T4P-targeting phages, while having no effect on a phage that recognises lipopolysaccharides as its receptor. Additionally, tuspetinib impedes T4P-mediated motility in <i>P. aeruginosa</i> and <i>Acinetobacter</i> species without impacting growth or flagellar motility. This bacterium-phage pairing approach is applicable to a broad range of virulence factors that are required for phage infection, paving ways for the development of advanced chemotherapeutics against antibiotic-resistant infections.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy","authors":"Rebecca F. Slykerman,&nbsp;Naomi Davies,&nbsp;Klara Vlckova,&nbsp;Kenneth J. O'Riordan,&nbsp;Shalome A. Bassett,&nbsp;James Dekker,&nbsp;Harriët Schellekens,&nbsp;Niall P. Hyland,&nbsp;Gerard Clarke,&nbsp;Elaine Patterson","doi":"10.1111/1751-7915.70079","DOIUrl":"10.1111/1751-7915.70079","url":null,"abstract":"<p>Advancing microbiome–gut–brain axis science requires systematic, rational and translational approaches to bridge the critical knowledge gaps currently preventing full exploitation of the gut microbiome as a tractable therapeutic target for gastrointestinal, mental and brain health. Current research is still marked by many open questions that undermine widespread application to humans. For example, the lack of mechanistic understanding of probiotic effects means it remains unclear why even apparently closely related strains exhibit different effects in vivo. For the therapeutic application of live microbial psychobiotics, consensus on their application as adjunct treatments to conventional neuromodulators, use in unmedicated populations or in at-risk cohorts with sub-clinical symptomatology is warranted. This missing information on both sides of the therapeutic equation when treating central nervous system (CNS) conditions makes psychobiotic research challenging, especially when compared to other pharmaceutical or functional food approaches. Expediting the transition from positive preclinical data to proven benefits in humans includes interpreting the promises and pitfalls of animal behavioural assays, as well as navigating mechanism-informed decision making to select the right microbe(s) for the job. In this review, we consider how these decisions can be supported in light of information accrued from a range of clinical studies across healthy, at-risk and pathological study populations, where specific strains have been evaluated in the context of gastrointestinal physiology, brain function and behaviour. Examples of successful, partial and unsuccessful translation from bench to bedside are considered. We also discuss the developments in in silico analyses that have enhanced our understanding of the gut microbiome and that have moved research towards pinpointing the host–microbe interactions most important for optimal gut–brain axis function. Combining this information with knowledge from functional assays across in vitro and ex vivo domains and incorporating model organisms can prime the discovery pipelines with the most promising and rationally selected psychobiotic candidates.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris","authors":"Sibel Kalyoncu,&nbsp;Dogu Sayili,&nbsp;Ayca Zeybek Kuyucu,&nbsp;Hakan Soyturk,&nbsp;Seyda Gullu,&nbsp;Busra Ersayan,&nbsp;Ibrahim Oguzhan Tarman,&nbsp;Mehmet Ender Avci,&nbsp;Olcay Mert,&nbsp;Umut Haskok,&nbsp;Ege Tekin,&nbsp;Huseyin Akinturk,&nbsp;Ridvan Orkut,&nbsp;Aysegul Demirtas,&nbsp;Idil Tilmensagir,&nbsp;Ceren Ulker,&nbsp;Bilgi Gungor,&nbsp;Mehmet Inan","doi":"10.1111/1751-7915.70077","DOIUrl":"10.1111/1751-7915.70077","url":null,"abstract":"<p>Low-cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. <i>Pichia pastoris</i> is an ideal expression system for recombinant protein production due to its cost-effective and easy-to-scale-up process. Here, we developed a next-generation SARS-CoV2 Omicron BA.1-based recombinant vaccine candidate expressed in <i>P. pastoris</i>. The receptor binding domain of Omicron BA.1 spike protein (RBD-Omicron) was produced at 0.35 g/L in supernatant. With a 60% recovery after two-step purification, RBD-Omicron showed 99% purity. After <i>in vitro</i> characterisation of purified RBD-Omicron via chromatography, mass spectrometry, calorimetry and surface plasmon resonance-based methods, it was injected into mice for immunization studies. Three different doses of Alum and CpG adjuvanted RBD-Omicron were investigated and 10 μg RBD-Omicron gave the highest antigenicity. After two doses of vaccination, IgG titers in mice serum reached to more than 10⁶. These serum antibodies also recognized earlier (Delta Plus: B.1.617.2) and later (Eris: EG.5, Pirola: BA.2.86) SARS-CoV2 variants. The long-term immunological response in mice was measured by analyzing serum antibody titers and T-cell response of splenocytes after 60 weeks. Interestingly, IgG titers and Th1 response were significantly high even after a year. Omicron subvariants are dominantly circulating in the world, so Omicron sub-lineage-based vaccines can be used for future pandemics. The RBD-Omicron-based vaccine candidate developed in this study is suitable for technology transfer and transition into the clinic.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food for Thoughts for Prospective Biomanufacturing","authors":"Ralf Takors","doi":"10.1111/1751-7915.70088","DOIUrl":"10.1111/1751-7915.70088","url":null,"abstract":"<p>While rising greenhouse gases cause climate change, global economies ask for resilient solutions for the business of the future. Biomanufacturing may well serve as a pillar of a circular economy with minimised environmental impact. Therefore, innovations of the lab need to successfully bridge the imminent ‘death-valley of innovation’ for making commercial production happen. This editorial aims to prepare the ground for prospective developments so as to the seed of novel ideas will prosper.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11727576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology","authors":"Kai Jin,&nbsp;Yi Huang,&nbsp;Hailong Che,&nbsp;Yihan Wu","doi":"10.1111/1751-7915.70080","DOIUrl":"10.1111/1751-7915.70080","url":null,"abstract":"<p>Using synthetic biology techniques, bacteria have been engineered to serve as microrobots for diagnosing diseases and delivering treatments. These engineered bacteria can be used individually or in combination as microbial consortia. The components within these consortia complement each other, enhancing diagnostic accuracy and providing synergistic effects that improve treatment efficacy. The application of microbial therapies in cancer, intestinal diseases, and metabolic disorders underscores their significant potential. The impact of these therapies on the host's native microbiota is crucial, as engineered microbes can modulate and interact with the host's microbial environment, influencing treatment outcomes and overall health. Despite numerous advancements, challenges remain. These include ensuring the long-term survival and safety of bacteria, developing new chassis microbes and gene editing techniques for non-model strains, minimising potential toxicity, and understanding bacterial interactions with the host microbiota. This mini-review examines the current state of engineered bacteria and microbial consortia in disease diagnosis and treatment, highlighting advancements, challenges, and future directions in this promising field.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}